GHRP-5
Experimental growth hormone releasing peptide (GHRP) with limited clinical data. Research compound used to investigate growth hormone secretion pathways and metabolic effects. Not approved for human use.
Research Status
Early Research
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Ghrelin receptor agonism stimulates appetite. Typically resolves within hours post-injection. Manage by planning meals in advance or eating before injection if appetite stimulation is undesirable.
Local inflammatory response at injection site. Usually resolves within 1-2 hours. Minimize by rotating sites, using proper injection technique, and allowing the solution to reach room temperature before injection.
Transient vasodilation associated with GH release. Typically occurs 15-30 minutes post-injection and resolves within 30-60 minutes.
May occur in response to rapid GH elevation. Usually mild and self-resolving. Ensure adequate hydration.
May occur with rapid GH secretion, particularly if injected while standing. Sit or lie down for 5-10 minutes post-injection if this occurs.
Transient increase in heart rate associated with GH release. Usually resolves within 30-60 minutes. Monitor if you have cardiovascular concerns.
Repeated GHRP dosing within 2-4 hours causes receptor desensitization and blunted GH response. Spacing doses 4-6+ hours apart or using intermittent dosing protocols (e.g., 5 days on, 2 days off) may help maintain responsiveness.
Chronic repeated injections at the same site can cause localized fat atrophy or hypertrophy. Prevent by strictly rotating injection sites with each dose and spacing injections at least 1 inch apart.
GHRPs may transiently elevate cortisol. Individuals with adrenal insufficiency or cortisol sensitivity should exercise caution. Not typically clinically significant with short-term use.
Some GHRPs may cause mild transient prolactin elevation. Clinically significant elevation is rare. Monitor if you have prolactin-sensitive conditions.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 100-200 mcg |
| Frequency | 1-3x daily |
| Timing | Before meals or before bed |
| Route | Subcutaneous |
Subcutaneous injection. Research compound only. Start at lower end (100 mcg) and assess response before increasing. Timing relative to meals may influence GH secretion response.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
GHRP-5 is a synthetic growth hormone releasing peptide that acts as a ghrelin receptor agonist (GHS-R1a), stimulating the release of growth hormone from the anterior pituitary gland. It works synergistically with endogenous growth hormone-releasing hormone (GHRH) to enhance GH secretion. The peptide mimics the action of ghrelin, a natural orexigenic hormone, triggering GH pulses independent of somatostatin inhibition.
Ghrelin Receptor (GHS-R1a) Activation
GHRP-5 binds to growth hormone secretagogue receptors on somatotroph cells in the anterior pituitary, triggering intracellular calcium mobilization and depolarization, leading to GH release.
GHRH Synergy
GHRP-5 potentiates the effect of endogenous GHRH, resulting in amplified GH secretion pulses compared to either stimulus alone.
Somatostatin Antagonism
GHRPs may partially inhibit somatostatin tone, reducing GH suppression and allowing greater GH secretion.
- GHRP-5 is a pentapeptide member of the growth hormone secretagogue family, distinct from GHRP-2 and GHRP-6.
- GH secretion response is dose-dependent and exhibits desensitization with repeated dosing over hours.
- Peak GH levels typically occur 15-60 minutes post-injection.
- Efficacy is enhanced when administered during fasting or in the evening (natural GH pulse timing).
Track your GHRP-5 research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. GHRP-5 is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.